id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
2299784_1 | A 59-year-old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed postoperative psychosis and was diagnosed as having bromide intoxication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"a large dose of pyridostigmine bromide\"]], \"start\": [[56]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"pyridostigmine bromide\"]], \"start\": [[72]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"myasthenia gravis\"]], \"start\": [[25]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"a large dose\"]], \"start\": [[56]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"postoperative psychosis and was diagnosed as having bromide intoxication.\"]], \"start\": [[105]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 59-year-old woman with myasthenia gravis\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"59-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
1743388_2 | This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and ulceration following the extravasation of intravenous pentamidine into the soft tissues of the left hand and forearm. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"chemical cellulitis and ulceration\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a renal transplant patient with Pneumocystis pneumonia\"]], \"start\": [[20]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"renal transplant\"]], \"start\": [[22]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"intravenous pentamidine into the soft tissues of the left hand and forearm\"]], \"start\": [[155]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Pneumocystis pneumonia\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[155]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"pentamidine\"]], \"start\": [[167]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
9701106_2 | Attempts were made to stop and then restart the theophylline therapy at progressively lower doses; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"became\"]], \"start\": [[162]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"theophylline therapy\"]], \"start\": [[48]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"theophylline\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"99.9 and 149.9 micromol/L\"], [\"18 and 27 microg/mL\"]], \"start\": [[228], [255]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[131]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"reaction to the drug became more toxic\"]], \"start\": [[141]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16298824_4 | Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"Dyspnea, hypoxemia, and pleuritic chest pain\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"rituximab administration\"]], \"start\": [[73]], \"entity_id\": [\"T8\"], \"Time_elapsed\": {\"text\": [[\"24 hours\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
11834188_3 | Dermatitis to captopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[14]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[14]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"Dermatitis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3067748_2 | Histological examination of the dacryolith suggested its derivation from breakdown products of adrenaline. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"dacryolith\"]], \"start\": [[32]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"breakdown products of adrenaline\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"adrenaline\"]], \"start\": [[95]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"suggested\"]], \"start\": [[43]], \"entity_id\": [\"T4\"], \"value\": true}}"
}
]
}
] |
515777_2 | Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"diabetic coma\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"a combination of a thiazide diuretic and propranolol\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"thiazide\"], [\"propranolol\"]], \"start\": [[68], [90]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[51]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"thiazide\"], [\"propranolol\"]], \"start\": [[68], [90]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
24318743_2 | Platinum-resistant ovarian cancer (PROC) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic agents. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[97]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"traditional cytotoxic agents\"]], \"start\": [[102]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"Platinum-resistant ovarian cancer (PROC)\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"traditional cytotoxic agents\"]], \"start\": [[102]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"limited efficacy\"]], \"start\": [[80]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
1310879_1 | A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[121]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"standard heparin\"]], \"start\": [[142]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[151]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure\"]], \"start\": [[44]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T16\"]}}"
}
]
}
] |
16116136_2 | Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"MG with MM\"]], \"start\": [[84]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"MG\"]], \"start\": [[84]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"MM\"]], \"start\": [[92]], \"entity_id\": [\"T4\"]}}, \"Effect\": {\"text\": [[\"increased risk of lymphoproliferative\"]], \"start\": [[118]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"may be\"]], \"start\": [[95]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
2616440_2 | We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute life-threatening water intoxication\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"oral indomethacin and low dose intravenous cyclophosphamide\"]], \"start\": [[135]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"multiple myeloma\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Route\": {\"text\": [[\"oral\"], [\"intravenous\"]], \"start\": [[135], [166]], \"entity_id\": [\"T9\", \"T12\"]}, \"Drug\": {\"text\": [[\"indomethacin\"], [\"cyclophosphamide\"]], \"start\": [[140], [178]], \"entity_id\": [\"T10\", \"T13\"]}, \"Dosage\": {\"text\": [[\"low dose\"]], \"start\": [[157]], \"entity_id\": [\"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[153]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"indomethacin\"], [\"cyclophosphamide\"]], \"start\": [[140], [178]], \"entity_id\": [\"T10\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"a patient with multiple myeloma\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"life-threatening\"]], \"start\": [[74]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
19145124_1 | Multifocal electroretinographic abnormalities in ethambutol-induced visual loss. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[49]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"visual loss\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17364199_7 | She was on etanercept and methotrexate for rheumatoid arthritis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"etanercept and methotrexate\"]], \"start\": [[11]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"etanercept\"], [\"methotrexate\"]], \"start\": [[11], [26]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[22]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"etanercept\"], [\"methotrexate\"]], \"start\": [[11], [26]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
1504404_1 | Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and hallucinations have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"consist\"]], \"start\": [[93]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"secondary to ciprofloxacin treatment\"]], \"start\": [[31]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"minor dizziness or mild headache, although rare occurrences of seizures and hallucinations\"]], \"start\": [[109]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
14585456_1 | We present a case of a 20-year-old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"ingested\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 20-year-old woman\"]], \"start\": [[21]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"20-year-old\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"900 mg of glyburide\"]], \"start\": [[54]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"900 mg\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"glyburide\"]], \"start\": [[64]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"refractory hypoglycemia\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7619765_1 | Etoposide-related myocardial infarction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Etoposide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Etoposide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"myocardial infarction\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12460237_5 | Contrary to previous recommendations, our experience cautions against the further use of high-dose cytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[181]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"high-dose cytarabine\"]], \"start\": [[89]], \"entity_id\": [\"T12\"], \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[89]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"cytarabine\"]], \"start\": [[99]], \"entity_id\": [\"T17\"]}, \"Disorder\": {\"text\": [[\"haematologic malignancies\"]], \"start\": [[287]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"PPE\"]], \"start\": [[134]], \"entity_id\": [\"T14\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[171]], \"entity_id\": [\"T18\"], \"value\": true}}"
}
]
}
] |
18607107_4 | She had been on Copaxone 20 mg/day treatment for 2 years when she first exhibited gastrointestinal symptoms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exhibited\"]], \"start\": [[72]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Copaxone 20 mg/day treatment for 2 years\"]], \"start\": [[16]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Copaxone\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"20 mg/day\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Duration\": {\"text\": [[\"2 years\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"gastrointestinal symptoms\"]], \"start\": [[82]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15795553_3 | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[63]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"elderly patient with mixed dementia\"]], \"start\": [[23]], \"entity_id\": [\"T11\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[23]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia)\"]], \"start\": [[73]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"abrupt withdrawal of risperidone therapy\"]], \"start\": [[188]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[209]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"mixed dementia\"]], \"start\": [[44]], \"entity_id\": [\"T18\"]}}}"
}
]
}
] |
20118434_1 | Interferon-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicated\"]], \"start\": [[90]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Interferon\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Interferon\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"neuropsychiatric symptoms\"]], \"start\": [[129]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[37]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
21416219_1 | Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"efficacy\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients with persistent elevated triglycerides\"]], \"start\": [[80]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"adding fenofibric acid to moderate-dose statin therapy\"]], \"start\": [[22]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"persistent elevated triglycerides\"]], \"start\": [[94]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"fenofibric acid\"], [\"statin\"]], \"start\": [[29], [62]], \"entity_id\": [\"T11\", \"T12\"]}, \"Dosage\": {\"text\": [[\"moderate-dose\"]], \"start\": [[48]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"adding\"]], \"start\": [[22]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"fenofibric acid\"], [\"statin\"]], \"start\": [[29], [62]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
18421192_3 | Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoked\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"peginterferon alpha-2b plus ribavirin treatment\"]], \"start\": [[37]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"peginterferon alpha-2b\"], [\"ribavirin\"]], \"start\": [[37], [65]], \"entity_id\": [\"T7\", \"T8\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"plus\"]], \"start\": [[60]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"ribavirin\"], [\"peginterferon alpha-2b\"]], \"start\": [[65], [37]], \"entity_id\": [\"T8\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"Type 1 diabetes mellitus\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17519584_1 | A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole/trimethoprim. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[173]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"61-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"early diffuse cutaneous scleroderma with myositis\"], [\"progressive interstitial pneumonia\"]], \"start\": [[23], [77]], \"entity_id\": [\"T10\", \"T11\"]}}, \"Treatment\": {\"text\": [[\"sulfamethoxazole/trimethoprim\"]], \"start\": [[180]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"sulfamethoxazole\"], [\"trimethoprim\"]], \"start\": [[180], [197]], \"entity_id\": [\"T12\", \"T13\"]}, \"Time_elapsed\": {\"text\": [[\"3 weeks after\"]], \"start\": [[159]], \"entity_id\": [\"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[196]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[197], [180]], \"entity_id\": [\"T13\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"generalized erythema with high fever\"]], \"start\": [[122]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18676387_1 | Serotonin toxicity caused by an interaction between fentanyl and paroxetine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Serotonin toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"an interaction between fentanyl and paroxetine\"]], \"start\": [[29]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"fentanyl\"], [\"paroxetine\"]], \"start\": [[52], [65]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"fentanyl\"], [\"paroxetine\"]], \"start\": [[52], [65]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
16637972_4 | The sub-conjunctival haematoma in a patient receiving warfarin can pose a significant management challenge. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"sub-conjunctival haematoma\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[54]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8071504_1 | Toxic optic neuropathy associated with ethambutol: implications for current therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Toxic optic neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15316423_3 | The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causation\"]], \"start\": [[122]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"venous thrombosis\"]], \"start\": [[139]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[104]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19875411_1 | One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[137]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"One week after the initial-dose of adalimumab (160 mg)\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"adalimumab\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"160 mg\"]], \"start\": [[47]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"One week\"]], \"start\": [[0]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"fulminant cardiomyopathy\"]], \"start\": [[149]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an acute exacerbation of Crohn's disease, the patient\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8071504_7 | RESULTS: Ethambutol, and to a lesser extent isoniazid, are both implicated in the development of visually related side effects. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[82]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Ethambutol\", \"isoniazid\"]], \"start\": [[9, 44]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"isoniazid\"], [\"Ethambutol\"]], \"start\": [[44], [9]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[21]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"Ethambutol\"], [\"isoniazid\"]], \"start\": [[9], [44]], \"entity_id\": [\"T10\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"visually related side effects\"]], \"start\": [[97]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
24163322_2 | We report a case of an inadvertent increase in the international normalized ratio (INR) after the addition of bismuth subsalicylate for the treatment of diarrhea in an enterally fed patient receiving warfarin therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[88]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"addition of bismuth subsalicylate\", \"warfarin therapy\"]], \"start\": [[98, 200]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"diarrhea\"]], \"start\": [[153]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"bismuth subsalicylate\"], [\"warfarin\"]], \"start\": [[110], [200]], \"entity_id\": [\"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"addition\"]], \"start\": [[98]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"bismuth subsalicylate\"], [\"warfarin\"]], \"start\": [[110], [200]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Subject\": {\"text\": [[\"an enterally fed patient\"]], \"start\": [[165]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"inadvertent increase in the international normalized ratio (INR)\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
7995001_1 | Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[40]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"triazolam\"]], \"start\": [[5]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"triazolam\"], [\"ketoconazole\"], [\"itraconazole\"]], \"start\": [[5], [84], [100]], \"entity_id\": [\"T13\", \"T15\", \"T16\"]}, \"Route\": {\"text\": [[\"Oral\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"hazardous\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[18]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
12776809_17 | LFT elevation is transient and the low risk of the SB-LOT therapy to increase LFT value can be limited when risk factors are considered. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"the low risk\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"SB-LOT\"]], \"start\": [[51]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"increase LFT value\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"SB-LOT\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[39]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
16012330_9 | Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"Nineteen cases\", \"children\"]], \"start\": [[0, 107]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"Nineteen\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[107]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"unusual enhanced vincristine neurotoxicity\"]], \"start\": [[18]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[72]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[72]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
16718947_3 | Extended-release tolterodine 4 mg/day was then prescribed to manage overactive bladder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Extended-release tolterodine 4 mg/day\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"overactive bladder\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Extended-release tolterodine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"4 mg/day\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
18067642_1 | Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone-induced hypothyroidism and that involution changes represent the hypofunctional status of this drug-induced disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[186]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[175]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"], [\"amiodarone\"]], \"start\": [[175], [61]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Effect\": {\"text\": [[\"hypothyroidism\"]], \"start\": [[194]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a single case\"]], \"start\": [[88]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"single\"]], \"start\": [[90]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7962394_4 | The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"the first case\"]], \"start\": [[29]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"danazol treatment of endometriosis\"]], \"start\": [[82]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"endometriosis\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2229534_1 | Awareness of this route of intoxication might be important in patients in whom neurologic or psychiatric symptoms develop while large amounts of lidocaine cream are being used. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[114]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"neurologic or psychiatric symptoms\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"large amounts of lidocaine cream are being used\"]], \"start\": [[128]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"lidocaine\"]], \"start\": [[145]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"cream\"]], \"start\": [[155]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"large amounts\"]], \"start\": [[128]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18648015_1 | Cephalosporin-induced leukopenia following rechallenge with cefoxitin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cefoxitin\", \"Cephalosporin\"]], \"start\": [[60, 0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Cephalosporin\"], [\"cefoxitin\"]], \"start\": [[0], [60]], \"entity_id\": [\"T6\", \"T7\"]}}, \"Effect\": {\"text\": [[\"leukopenia\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17266059_2 | Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Thrombotic thrombocytopenic purpura\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"trimethoprim-sulfamethoxazole\"]], \"start\": [[47]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"trimethoprim-sulfamethoxazole\"]], \"start\": [[47]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a Jehovah's Witness\"]], \"start\": [[80]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17039658_2 | This eruption appears to be a distinct cutaneous toxicity of PLD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"eruption\", \"distinct cutaneous toxicity\"]], \"start\": [[5, 30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"PLD\"]], \"start\": [[61]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"PLD\"]], \"start\": [[61]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"appears\"]], \"start\": [[14]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
11999915_2 | Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"among\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Granulocytopenia and agranulocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[96]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
20298401_5 | RESULTS: We recently experienced a case of fatal erlotinib-induced ILD, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[49]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"ILD\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with radiation fibrosis\"]], \"start\": [[143]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"radiation fibrosis\"]], \"start\": [[158]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[43]], \"entity_id\": [\"T1\"], \"value\": \"High\"}}"
}
]
}
] |
15482394_5 | Unusual hypersensitivity to warfarin in a critically ill patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"a critically ill patient\"]], \"start\": [[40]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"critically ill\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Unusual hypersensitivity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
7914463_1 | Flumazenil reversal of benzodiazepine-induced sedation for a patient with severe pre-ECT anxiety. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"benzodiazepine\"]], \"start\": [[23]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"benzodiazepine\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"sedation\"]], \"start\": [[46]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with severe pre-ECT anxiety\"]], \"start\": [[59]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"severe pre-ECT anxiety\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"reversal\"]], \"start\": [[11]], \"entity_id\": [\"T15\"]}, \"Subject\": {\"text\": [[\"a patient with severe pre-ECT anxiety\"]], \"start\": [[59]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"severe pre-ECT anxiety\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"Flumazenil\"]], \"start\": [[0]], \"entity_id\": [\"T17\"], \"Disorder\": {\"text\": [[\"benzodiazepine-induced sedation\"]], \"start\": [[23]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"Flumazenil\"]], \"start\": [[0]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
11030530_3 | We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"seizure\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase therapy\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15316423_2 | Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a patient with Crohn's disease\"]], \"start\": [[17]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"infliximab infusion\"]], \"start\": [[201]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[201]], \"entity_id\": [\"T18\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[212]], \"entity_id\": [\"T19\"]}, \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[32]], \"entity_id\": [\"T20\"]}}, \"Effect\": {\"text\": [[\"severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral\"]], \"start\": [[64]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
16167682_1 | She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"despite\"]], \"start\": [[114]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"regular use of desferrioxamine\"]], \"start\": [[122]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"desferrioxamine\"]], \"start\": [[137]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"haemosiderosis\"]], \"start\": [[99]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"died within six weeks of developing congestive heart failure coupled with liver failure\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}, \"Negated\": {\"text\": [[\"died\"]], \"start\": [[4]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
14740795_1 | A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[105]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 56-year-old Caucasian man\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"56-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Race\": {\"text\": [[\"Caucasian\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[115]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"concomitant chemotherapy and radiation for head and neck cancer\", \"concurrent with the administration of amifostine\"]], \"start\": [[41, 121]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"head and neck cancer\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"amifostine\"], [\"radiation\"], [\"chemotherapy\"]], \"start\": [[159], [70], [53]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concurrent\"]], \"start\": [[121]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"amifostine\"], [\"radiation\"], [\"chemotherapy\"]], \"start\": [[159], [70], [53]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}}]}}"
}
]
}
] |
15806568_1 | In this study, we report on three individual patients who received BTX-B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX-B at remote sites. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[94]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"three individual patients\"]], \"start\": [[28]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"BTX-B\", \"BTX-B\"]], \"start\": [[67, 173]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"BTX-B\"], [\"BTX-B\"]], \"start\": [[67], [173]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Effect\": {\"text\": [[\"parasympathetic dysfunction of the visual system\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11026106_2 | Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Minocycline\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"sporadic autoimmune hepatitis\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Minocycline\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"autoimmune hepatitis\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10891991_2 | BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[154]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"women\"]], \"start\": [[148]], \"entity_id\": [\"T10\"], \"Gender\": {\"text\": [[\"women\"]], \"start\": [[148]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"sodium valproate for epilepsy\"]], \"start\": [[167]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"sodium valproate\"]], \"start\": [[167]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[188]], \"entity_id\": [\"T16\"]}}, \"Speculated\": {\"text\": [[\"seem\"]], \"start\": [[124]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
2621382_3 | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and onycholysis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"showed\"]], \"start\": [[103]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Two cases of lepromatous leprosy with erythema nodosum leprosum\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"high doses of clofazimine\"]], \"start\": [[76]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"lepromatous leprosy with erythema nodosum leprosum\"]], \"start\": [[13]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"clofazimine\"]], \"start\": [[90]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"high doses\"]], \"start\": [[76]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"discoloration of nail plate, subungual hyperkeratosis and onycholysis\"]], \"start\": [[110]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
14711147_1 | Doxycycline-induced photo-onycholysis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Doxycycline\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Doxycycline\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"photo-onycholysis\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
20203465_1 | Case report: acute renal failure after administering intravenous immunoglobulin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"administering intravenous immunoglobulin\"]], \"start\": [[39]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"immunoglobulin\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[53]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15224368_1 | Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sargramostim (granulocyte-macrophage colony stimulating factor) treatment\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sargramostim\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Sweet's syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16416684_1 | This is a rare case of ARDS associated with lithium intoxication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"ARDS\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"rare case\"]], \"start\": [[10]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
8520081_1 | Intravenous haloperidol is generally well tolerated, but multiform ventricular tachycardia has been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[100]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Intravenous haloperidol\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"multiform ventricular tachycardia\"]], \"start\": [[57]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
12243603_2 | To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"coadministration of atorvastatin and diltiazem\"]], \"start\": [[75]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"atorvastatin\"], [\"diltiazem\"]], \"start\": [[95], [112]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministration\"]], \"start\": [[75]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"atorvastatin\"], [\"diltiazem\"]], \"start\": [[95], [112]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"rhabdomyolysis and acute hepatitis\"]], \"start\": [[20]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
18094347_8 | Ten hours after the second methotrexate injection, the patient experienced a diffuse pruritic papular eruption located mainly on the limbs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"diffuse pruritic papular eruption located mainly on the limbs\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[51]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ten hours after the second methotrexate injection\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"Ten hours\"], [\"second\"]], \"start\": [[0], [20]], \"entity_id\": [\"T9\", \"T10\"]}}}"
}
]
}
] |
19531695_10 | Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[87]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"susceptible patients\"]], \"start\": [[105]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"delirium\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Flecainide and pharmacologically similar agents that interact with sodium channels\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[83]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
921427_1 | An elderly man with procainamide hydrochloride-induced lupus syndrome had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[47]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"procainamide hydrochloride\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"procainamide hydrochloride\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"lupus\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"An elderly man\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[11]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7151655_1 | In one patient, treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 h later. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"one patient\"]], \"start\": [[3]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"DCA\"]], \"start\": [[31]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"DCA\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"16 h later\"]], \"start\": [[130]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"decrease in blood lactate levels\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7865488_3 | We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"noncardiogenic pulmonary edema\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"EO\"]], \"start\": [[88]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"EO\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"esophageal varix\"]], \"start\": [[115]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
15878975_3 | That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complications\"]], \"start\": [[101]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"receiving anti-D IGIV\"]], \"start\": [[36]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"anti-D IGIV\"]], \"start\": [[46]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"hemoglobinemia, particularly disseminated intravascular coagulation (DIC)\"]], \"start\": [[118]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[91]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
11144696_1 | Seizures associated with therapeutic doses of venlafaxine and trimipramine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"therapeutic doses of venlafaxine and trimipramine\"]], \"start\": [[25]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[46], [62]], \"entity_id\": [\"T8\", \"T10\"]}, \"Dosage\": {\"text\": [[\"therapeutic doses\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[46], [62]], \"entity_id\": [\"T8\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"Seizures\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
14960440_1 | BACKGROUND: The risk/benefit ratio of warfarin therapy changes in the over 75s, when haemorrhagic side-effects become more common. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"become\"]], \"start\": [[111]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"warfarin therapy\"]], \"start\": [[38]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"haemorrhagic side-effects\"]], \"start\": [[85]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"over 75s\"]], \"start\": [[70]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"over 75s\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
1445134_5 | Norethisterone in these 69 pregnancies accounted for 33.3% (5 of 15) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"accounted\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Norethisterone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Norethisterone\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"69 pregnancies\"]], \"start\": [[24]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"69\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"clitoral hypertrophy\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
736591_1 | Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Interstitial fibrosis of the lung\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[65]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"psoriasis\"]], \"start\": [[90]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
22735246_5 | This is the first reported fatality due to this drug interaction and only the second case of serotonin syndrome reported with oxcarbazepine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[112]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[93]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[126]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[126]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15239684_1 | Purple glove syndrome, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[143]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Purple glove syndrome\", \"purple discoloration and swelling of the hands in the distribution of a glove\"]], \"start\": [[0, 49]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"intravenous phenytoin administration through small dorsal veins of the hands\"]], \"start\": [[159]], \"entity_id\": [\"T9\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[159]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[171]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
11483161_1 | Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"linkage\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"an HIV-infected hemophiliac\"]], \"start\": [[61]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amprenavir\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amprenavir\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[64]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"intracranial bleeding\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"Possible\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
8098286_2 | Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis, 10 weeks after drug readministration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"led to\"]], \"start\": [[51]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Inadvertent subsequent rechallenge with celiprolol\", \"10 weeks after drug readministration\"]], \"start\": [[0, 89]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"celiprolol\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"10 weeks\"]], \"start\": [[89]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"recurrence of the pneumonitis\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19531695_5 | Flecainide had been started 2 weeks prior for atrial fibrillation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"atrial fibrillation\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
18396749_4 | In the absence of evidence of a potential role for concomitant medication i.e. hydroxychloroquine sulfate to play a role in the clinical, biochemical and morphological picture, an interaction between the herbal preparation and tibolone was suspected as the likely cause of liver damage. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suspected\"]], \"start\": [[240]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"an interaction between the herbal preparation and tibolone\"]], \"start\": [[177]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"herbal preparation\"], [\"tibolone\"]], \"start\": [[204], [227]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[180]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"herbal preparation\"], [\"tibolone\"]], \"start\": [[204], [227]], \"entity_id\": [\"T13\", \"T14\"]}}]}, \"Effect\": {\"text\": [[\"liver damage\"]], \"start\": [[273]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[240]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
9128433_1 | Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[260]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with APL\"]], \"start\": [[237]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"symptom complex referred to as \\\"retinoic acid syndrome.\\\"\"]], \"start\": [[158]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis\"]], \"start\": [[283]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"ATRA\"]], \"start\": [[335]], \"entity_id\": [\"T13\"]}, \"Time_elapsed\": {\"text\": [[\"a few weeks\"]], \"start\": [[283]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"APL\"]], \"start\": [[252]], \"entity_id\": [\"T15\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[152]], \"entity_id\": [\"T16\"], \"value\": \"High\"}}"
}
]
}
] |
18609153_2 | During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[145]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a 50-year-old male with no history of heart disease\"]], \"start\": [[93]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"50-year-old\"]], \"start\": [[95]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[107]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"a newly prolonged QT interval and torsade de pointes\"]], \"start\": [[155]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[7]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"terlipressin\"]], \"start\": [[34]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"recurrent gastrointestinal\"]], \"start\": [[51]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
1109248_9 | It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caution\"]], \"start\": [[100]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"chloral hydrate and methaqualone\", \"during oral anticoagulant therapy\"]], \"start\": [[21, 139]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"chloral hydrate\"], [\"methaqualone\"], [\"anticoagulant\"]], \"start\": [[21], [41], [151]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[146]], \"entity_id\": [\"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[37]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"chloral hydrate\"], [\"methaqualone\"], [\"anticoagulant\"]], \"start\": [[21], [41], [151]], \"entity_id\": [\"T13\", \"T14\", \"T15\"]}}]}, \"Speculated\": {\"text\": [[\"may be\"]], \"start\": [[54]], \"entity_id\": [\"T7\"], \"value\": true}, \"Negated\": {\"text\": [[\"without\"]], \"start\": [[81]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
6692713_1 | Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Amiodarone hydrochloride\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"Amiodarone hydrochloride\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates\"]], \"start\": [[79]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
9831311_1 | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"major hazards\"]], \"start\": [[9]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"hypophosphatemic osteomalacia with phosphate and calcitriol\"]], \"start\": [[39]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"phosphate\"], [\"calcitriol\"]], \"start\": [[74], [88]], \"entity_id\": [\"T13\", \"T14\"]}, \"Disorder\": {\"text\": [[\"hypophosphatemic osteomalacia\"]], \"start\": [[39]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[84]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"phosphate\"], [\"calcitriol\"]], \"start\": [[74], [88]], \"entity_id\": [\"T13\", \"T14\"]}}]}, \"Effect\": {\"text\": [[\"secondary hyperparathyroidism and vitamin D intoxication, potassium loss\"]], \"start\": [[103]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
19579947_1 | He had priapism following the use of olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"priapism\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[37]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
20298401_10 | CONCLUSION: Our case shows a fatal side effect of erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"side effect\"]], \"start\": [[35]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[29]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
2161782_1 | Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"responsible\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[56]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"subsequent development of carcinoma of the corpus uteri\"]], \"start\": [[93]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"these patients\"]], \"start\": [[152]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[66]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
16404563_3 | Corticosteroids may be useful for therapy of some features of this syndrome, such as thrombocytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"be useful\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Corticosteroids\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Corticosteroids\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[85]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[16]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
15183980_1 | Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bladder instillation with dimethyl sulfoxide\"]], \"start\": [[28]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dimethyl sulfoxide\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"bladder instillation\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Eosinophilic cystitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11881322_1 | Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"responsible\"]], \"start\": [[79]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"ductopenia\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"prolonged drug-induced cholangiopathy\"]], \"start\": [[113]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"two\"]], \"start\": [[36]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"might be\"]], \"start\": [[70]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
576675_1 | A 15-kg weight gain developed in a patient during the third week of ibuprofen therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"A 15-kg weight gain\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\"]], \"start\": [[68]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"the third week\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7019786_1 | Cefoxitin-associated renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Cefoxitin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Cefoxitin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"renal failure\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9169264_4 | The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"seen\"]], \"start\": [[9]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cephalexin\"]], \"start\": [[52]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cephalexin\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"rash\"]], \"start\": [[4]], \"entity_id\": [\"T4\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"seen\"]], \"start\": [[91]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"ampicillin treatment\"]], \"start\": [[101]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[101]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[125]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"infectious mononucleosis\"]], \"start\": [[139]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
15644988_2 | Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy, respectively. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Two of our patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"TD\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ziprasidone\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ziprasidone\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"23 months\"], [\"34 months\"]], \"start\": [[39], [53]], \"entity_id\": [\"T9\", \"T10\"]}}}"
}
]
}
] |
12932249_3 | We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"combination therapy with IFN and ribavirin.\"]], \"start\": [[98]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"IFN\"], [\"ribavirin\"]], \"start\": [[123], [131]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[98]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"IFN\"], [\"ribavirin\"]], \"start\": [[123], [131]], \"entity_id\": [\"T13\", \"T14\"]}}]}, \"Subject\": {\"text\": [[\"two dark-skinned patients\"]], \"start\": [[12]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}, \"Race\": {\"text\": [[\"dark-skinned\"]], \"start\": [[16]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"hyperpigmented skin and tongue lesions\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
2643458_1 | Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation\"]], \"start\": [[56]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Erwinia carotovora\"], [\"Escherichia coli enzyme preparation\"]], \"start\": [[76], [103]], \"entity_id\": [\"T6\", \"T7\"]}}, \"Effect\": {\"text\": [[\"Attenuation of asparaginase-induced hyperglycemia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10749332_2 | It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"troglitazone\"]], \"start\": [[65]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"troglitazone\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"whether\"]], \"start\": [[22]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
2935070_1 | Ampicillin-induced interstitial nephritis with generalised exfoliative dermatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Ampicillin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Ampicillin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"interstitial nephritis with generalised exfoliative dermatitis\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
7900744_3 | High-dose intravenous mannitol infusion in various clinical settings may result in acute renal failure (ARF). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"High-dose intravenous mannitol infusion\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"mannitol\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"intravenous\", \"infusion\"]], \"start\": [[10, 31]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"High-dose\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[69]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
6416845_1 | A 7-year-old boy developed a severe unilateral grand mal seizure at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"therapy\"]], \"start\": [[186]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 7-year-old boy developed a severe unilateral grand mal seizure\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"7-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[13]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"a severe unilateral grand mal seizure\"]], \"start\": [[27]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.\"]], \"start\": [[65]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"phenobarbitone\"], [\"valproate\"]], \"start\": [[88], [129]], \"entity_id\": [\"T12\", \"T13\"]}, \"Time_elapsed\": {\"text\": [[\"1.5 years later\"]], \"start\": [[113]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[173]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"valproate\"], [\"phenobarbitone\"]], \"start\": [[129], [88]], \"entity_id\": [\"T13\", \"T12\"]}}]}}"
}
]
}
] |
19474653_2 | We report the first case of rhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related to\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"administration of clarithromycin without concurrent use of other medications\"]], \"start\": [[58]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clarithromycin\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
3804181_2 | The authors report a further case of methimazole-associated liver damage and present a brief review of eleven previous cases found in the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methimazole\"]], \"start\": [[37]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"methimazole\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"liver damage\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a further case\", \"eleven previous cases\"]], \"start\": [[19, 103]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"eleven\"]], \"start\": [[103]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2051906_1 | A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[97]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"67-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T1\"]}}, \"Treatment\": {\"text\": [[\"3 months after initiation of azathioprine\"]], \"start\": [[163]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"azathioprine\"]], \"start\": [[192]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"3 months\"]], \"start\": [[163]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"primary polymyositis\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"cholestasis\"]], \"start\": [[151]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[144]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
3569037_2 | Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[26]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with typhoid fever\"]], \"start\": [[70]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Hypersensitivity reaction\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"chloramphenicol\"]], \"start\": [[36]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"chloramphenicol\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"typhoid fever\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10357715_1 | Allergic and irritant contact dermatitis to calcipotriol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"contact dermatitis\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"calcipotriol\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"calcipotriol\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"Allergic and irritant\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"Medium\"}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.